// App-Quantinova.ai

AB0484 (2022) : CLINICAL EFFICACY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Researchers

Presenter

  • G. Tarasova

Principal Investigators

  • B. Belov

  • O. Egorova

  • T. Reshetnyak

Medical Centers

  • V.A. Nasonova Research Institute of Rheumatology, Laboratory of Vascular Rheumatology, Moscow, Russian Federation

  • VA Nasonova Research Institute of Rheumatology, Department of Comorbid Infections and Vaccine Prevention, Moscow, Russian Federation

  • Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Department of Rheumatology, Moscow, Russian Federation

Locations

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • Myozenin 2

  • BLM helicase

Drug/Treatment

  • Pneumococcal polysaccharide vaccine

  • Hydroxychloroquine

  • Glucocorticoid

  • Belimumab

  • Rituximab

  • PPV-23

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved